Respiratory Tract Neoplasms
Information
- Disease name
- Respiratory Tract Neoplasms
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05241873 | Active, not recruiting | Phase 1/Phase 2 | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | March 4, 2022 | July 25, 2026 |
| NCT02871856 | Active, not recruiting | N/A | International Lung Screen Trial (ILST) | April 5, 2017 | December 2025 |
| NCT04862780 | Active, not recruiting | Phase 1/Phase 2 | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | June 29, 2021 | January 31, 2025 |
| NCT04222972 | Active, not recruiting | Phase 3 | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | July 24, 2020 | June 30, 2025 |
| NCT03037385 | Completed | Phase 1/Phase 2 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | March 17, 2017 | March 21, 2024 |
| NCT03134872 | Completed | Phase 3 | A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC | May 12, 2017 | August 29, 2019 |
| NCT00990535 | Completed | Phase 2 | High Dose Somatostatin Analogues in Neuroendocrine Tumors | January 2006 | December 2008 |
| NCT01039948 | Completed | Phase 1/Phase 2 | A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | December 2009 | August 2013 |
| NCT02897778 | Completed | Phase 1 | Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors | August 24, 2016 | March 13, 2017 |
| NCT02909452 | Completed | Phase 1 | Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | September 20, 2016 | February 9, 2021 |
| NCT06376084 | Not yet recruiting | Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC | July 24, 2024 | February 28, 2028 | |
| NCT06004440 | Recruiting | Real World Registry for Use of the Ion Endoluminal System | September 21, 2023 | August 2027 | |
| NCT04776447 | Recruiting | Phase 2 | Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) | June 16, 2021 | November 15, 2027 |
| NCT06177925 | Recruiting | Phase 2 | A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC | December 10, 2023 | September 30, 2026 |
| NCT05153408 | Terminated | Phase 1 | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | January 13, 2022 | December 9, 2022 |
| NCT04644315 | Terminated | Phase 2 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | May 24, 2021 | May 16, 2022 |
| NCT02431962 | Unknown status | N/A | Alberta Lung Cancer Screening Program | April 2015 | December 2022 |
| NCT03402048 | Unknown status | Phase 3 | The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial | July 2012 | May 2021 |
| NCT04697446 | Unknown status | External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC | December 1, 2020 | October 31, 2021 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D012142